valsartan has been researched along with cardiovascular agents in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 29 (72.50) | 24.3611 |
| 2020's | 7 (17.50) | 2.80 |
| Authors | Studies |
|---|---|
| Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P | 1 |
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| Goa, KL; Wellington, K | 1 |
| Alonso, RM; Ferreirós, N; Gonzalez, O; Iriarte, G; Jiménez, RM; Maguregui, MI | 1 |
| Chen, JW; Fang, J; Gao, J; Huang, HQ; Liu, PQ; Tang, FT; Wang, P; Xu, SW; Zhou, SG | 1 |
| Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN | 1 |
| Chai, J; Guo, G; Hao, D; Song, F; Zhao, Y | 1 |
| Nguyen, E; Weeda, ER; White, CM | 1 |
| Latini, R; Masson, S; Staszewsky, L | 1 |
| Korabathina, R; Wojnowich, K | 1 |
| Patel, S; Veltri, K | 1 |
| Hein, L; Lother, A | 1 |
| Rosenberg, K | 1 |
| Adhyaru, B; Raj, L | 1 |
| Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH | 1 |
| Lin, JX; Lin, LM; Wu, MF; Wu, Y | 1 |
| Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL | 1 |
| Butler, J; Hamo, CE; Papadimitriou, L | 2 |
| De Biase, L; Emdin, M; Senni, M; Trimarco, B | 1 |
| Butler, J; Papadimitriou, L | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Clem, JR; Heins, J | 1 |
| Chien, FJ; Eisen, HJ; Kim, DH | 1 |
| Briggs, A; Cowie, MR; Deschaseaux, C; Hancock, E; Haroun, R; Lacey, M; McMurray, JJV; Mumby-Croft, J; Taylor, M; Trueman, D; Woodcock, F | 1 |
| Brink, D | 1 |
| Kuehn, BM | 1 |
| Adda, J; Akodad, M; Audurier, Y; Battistella, P; Belloc, C; Breuker, C; Castet-Nicolas, A; Chettouh, M; Cristol, JP; Curinier, C; Dupuy, AM; Fesler, P; Kalmanovich, E; Kuster, N; Lotierzo, M; Marques, S; Mercier, G; Roubille, C; Roubille, F; Solecki, K; Soltani, S; Verchere, A; Zerkowski, L | 1 |
| Coppey, LJ; Davidson, EP; Obrosov, A; Shevalye, H; Yorek, MA | 1 |
| Zacà, V | 1 |
| Amurthur, B; Anand, IS; Ardell, JL; DiCarlo, LA; Gregory, DD; KenKnight, BH; Libbus, I; Mittal, S; Monteiro, R; Premchand, RK; Sharma, K | 1 |
| Bobadilla, G; Bravo, C; Duarte, M; Guardamagna, C; Muñoz, P; Rossel, V; Verdugo, F | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| Jorsal, A; McMurray, JJV; Nielsen, JC; Nielsen, RR; Pryds, K; Sommer, A; Wiggers, H | 1 |
| Ajufo, E; Das, SR; Fonarow, GC; Navar, AM; Pandey, A; Sumarsono, A; Vaduganathan, M | 1 |
| Dickert, NW; Moore, MA; Morris, AA; Rao, BR; Shore, S; Smith, GH; Speight, CD | 1 |
| Brown, NJ; Garner, EM; Hubers, SA; Kerman, SJ; Mashayekhi, M; Nian, H; Ramirez Bustamante, CE; Shibao, CA; Wilson, JR | 1 |
| Chai, HT; Chen, CH; Chen, YL; Chiang, JY; Sung, PH; Yang, CC; Yip, HK | 1 |
| Slomski, A | 1 |
| Billaud, EM; Boutouyrie, P; De Sousa Carvalho, C; Derobertmasure, A; Justin, J; Kably, B | 1 |
14 review(s) available for valsartan and cardiovascular agents
| Article | Year |
|---|---|
Valsartan: in chronic heart failure.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Agents; Drug Administration Schedule; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Medication Therapy Management; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Heart Failure Update: Outpatient Management.
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiotonic Agents; Cardiovascular Agents; Diet, Sodium-Restricted; Digoxin; Diuretics; Drug Combinations; Exercise Therapy; Fatty Acids, Omega-3; Female; Heart Failure; Heart Transplantation; Hospice Care; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Tetrazoles; Valsartan; Vasodilator Agents | 2016 |
New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Pharmacology of heart failure: From basic science to novel therapies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Guanylate Cyclase; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Myosins; Neprilysin; Practice Guidelines as Topic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents | 2016 |
Evolving therapies for the management of chronic and acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan | 2016 |
Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Contraindications; Cost-Benefit Analysis; Drug Combinations; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renal Insufficiency, Chronic; Tetrazoles; Valsartan | 2016 |
Heart failure guidelines: What's new?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Drug Combinations; Guideline Adherence; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Heart Failure Guidelines on Pharmacotherapy.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Diuretics; Drug Combinations; Heart Failure; Humans; Hydralazine; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Nitrates; Practice Guidelines as Topic; Severity of Illness Index; Stroke Volume; Tetrazoles; Valsartan; Vasodilator Agents | 2017 |
"Fast Track" Development and Approval Process for Heart Failure Therapeutics.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Approval; Drug Combinations; Drug Discovery; Heart Failure; Humans; Ivabradine; Tetrazoles; United States; United States Food and Drug Administration; Valsartan | 2017 |
Pharmacologic Management for Heart Failure and Emerging Therapies.
Topics: Aminobutyrates; Benzazepines; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Glucosides; Heart Failure; Humans; Ivabradine; Neuregulin-1; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Urea; Valsartan | 2017 |
Heart failure treatment: Keeping up with best practices.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cardiac Rehabilitation; Cardiac Resynchronization Therapy; Cardiovascular Agents; Defibrillators, Implantable; Diuretics; Drug Combinations; Echocardiography; Heart Failure; Heart-Assist Devices; Humans; Ivabradine; Obesity; Physician's Role; Physicians, Family; Sleep Apnea, Obstructive; Stroke Volume; Tetrazoles; Valsartan | 2018 |
7 trial(s) available for valsartan and cardiovascular agents
| Article | Year |
|---|---|
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1999 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan | 2015 |
Evaluation of the sST2-guided optimization of medical treatments of patients admitted for heart failure, to prevent readmission: Study protocol for a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Ivabradine; Male; Mineralocorticoid Receptor Antagonists; Patient Care Planning; Patient Readmission; Sodium Potassium Chloride Symporter Inhibitors; Tetrazoles; Valsartan | 2018 |
Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Autonomic Nervous System; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Practice Guidelines as Topic; Quality of Life; Stroke Volume; Tetrazoles; Treatment Outcome; Vagus Nerve Stimulation; Valsartan; Ventricular Function, Left; Walk Test | 2019 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
Optimizing heart failure treatment following cardiac resynchronization therapy.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2020 |
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Aprepitant; Blood Pressure; Cardiovascular Agents; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Humans; Norepinephrine; Ramipril; Renin-Angiotensin System; Sitagliptin Phosphate; Valsartan | 2022 |
19 other study(ies) available for valsartan and cardiovascular agents
| Article | Year |
|---|---|
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma.
Topics: Cardiovascular Agents; Chlorthalidone; Chromatography, Liquid; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension.
Topics: Abietanes; Animals; Blood Pressure; Cardiovascular Agents; Collagen; Drugs, Chinese Herbal; Fibrosis; Gene Expression; Heart; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocardium; Phytotherapy; Rats; Rats, Sprague-Dawley; RNA, Messenger; Salvia miltiorrhiza; Tetrazoles; Tissue Inhibitor of Metalloproteinase-1; Valine; Valsartan | 2010 |
Effectiveness evaluation of cardiovascular drugs based on CYP2C9 target protein.
Topics: Cardiovascular Agents; Cytochrome P-450 CYP2C9; Fuzzy Logic; Humans; Tetrazoles; Valine; Valsartan | 2015 |
New Recommendations for Heart Failure Treatment.
Topics: Antihypertensive Agents; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Valsartan | 2016 |
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan | 2016 |
[Sacubitril/valsartan, a new and effective treatment for heart failure with reduced ejection fraction].
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Combination cardiovascular drugs.
Topics: Aminobutyrates; Amlodipine; Aspirin; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Nebivolol; Omeprazole; Perindopril; Tetrazoles; Valsartan | 2017 |
Evolving Pharmacologic Therapies for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Ivabradine; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2017 |
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Colombia; Cost-Benefit Analysis; Denmark; Drug Combinations; Drug Costs; Heart Failure; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United Kingdom; Valsartan; Ventricular Function, Left | 2018 |
High Costs and Caution Yield Slow Start for New Heart Drugs.
Topics: Aminobutyrates; Animals; Biphenyl Compounds; Cardiovascular Agents; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Drug Discovery; Drug Industry; Health Services Accessibility; Healthcare Disparities; Humans; Practice Patterns, Physicians'; Risk Assessment; Tetrazoles; Valsartan | 2018 |
Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Diabetic Retinopathy; Diet, High-Fat; Disease Progression; Drug Combinations; Male; Neprilysin; Neural Conduction; Neuroprotective Agents; Protease Inhibitors; Rats, Sprague-Dawley; Tetrazoles; Valsartan; Vascular Resistance | 2018 |
Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Cost-Benefit Analysis; Defibrillators, Implantable; Drug Combinations; Drug Costs; Electric Countershock; Female; Health Care Costs; Heart Failure; Hospital Costs; Hospitalization; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Economic; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2018 |
[Proportion of patients with heart failure in a specialized clinic eligible for novel therapies].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Patient Selection; Tetrazoles; Valsartan | 2019 |
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Drug Utilization; Heart Failure; Humans; Ivabradine; Medicaid; Medicare Part D; Tetrazoles; United States; Valsartan | 2020 |
Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.
Topics: Adult; Aged; Aminobutyrates; Attitude of Health Personnel; Biphenyl Compounds; Cardiovascular Agents; Choice Behavior; Decision Making, Shared; Drug Combinations; Drug Costs; Female; Health Expenditures; Health Knowledge, Attitudes, Practice; Heart Failure; Humans; Interviews as Topic; Male; Middle Aged; Patient Participation; Patient Preference; Patient-Centered Care; Physician-Patient Relations; Tetrazoles; Valsartan | 2020 |
Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Topics: Aminobutyrates; Animals; Apoptosis; Biphenyl Compounds; Cardio-Renal Syndrome; Cardiovascular Agents; Drug Combinations; Fibrosis; Humans; Inflammation; Kidney; Male; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Simendan; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Sacubitril-Valsartan and Heart Function in End-stage Kidney Disease.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Kidney Failure, Chronic; Stroke Volume; Valsartan | 2022 |
Dried Urine Spot Analysis for assessing cardiovascular drugs exposure applicable in spaceflight conditions.
Topics: Cardiovascular Agents; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Irbesartan; Reproducibility of Results; Tandem Mass Spectrometry; Valsartan | 2023 |